Gilead Sciences Inc. (NASDAQ:GILD) is one of the undervalued S&P 500 stocks to buy according to hedge funds. On June 25, ...

Shares of Gilead rose nearly 3% after the U.S. Supreme Court on Friday preserved a key element of the Obamacare law that ...

The core value driver remains KT-621, Kymera’s STAT6-targeting program. “STAT6 remains [the] primary driver to the story,” ...

Merck announced ACIP voted to recommend Enflosnia (clesrovimab-cfor) as a treatment option for RSV in infants younger than 8 months of age who are born during or entering their first RSV season.

Detailed price information for Gilead Sciences Inc (GILD-Q) from The Globe and Mail including charting and trades.

Gilead Sciences and Kymera Therapeutics have entered into a partnership worth as much as $750m to develop a molecular glue ...

Gilead Sciences, Inc. and Kymera Therapeutics, Inc., have entered into an exclusive option and license agreement for ...

This press release shall not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, ...

Kymera intends to use the net proceeds from the offering to continue to advance its pipeline of preclinical and clinical degrader programs that are designed to address large patient populations with ...

Given that there is no confirmed CDC director and a small newly appointed panel with many members lacking a broad vaccine or immunology knowledge, “there are concerns about the rushed nature of this ...

Kymera Therapeutics, Inc.'s stock rose on KT-621 data, but Sanofi's exit casts doubts. A Gilead Sciences, Inc. deal offers ...